Tropisetron

Dual 5-HT3 antagonist and α7 nAChR partial agonist. Nicotine’s addiction and dopaminergic drive come from its α4β2 bias, so a selective α7 partial agonist sidesteps that entirely. GTS-21 validated the α7 mechanism in healthy men: working memory, episodic memory, and sustained attention all improved (Kitagawa et al., 2003; van Haaren et al., 1999). Tropisetron replicates and extends these effects in primates and schizophrenic patients (Callahan et al., 2017; Xia et al., 2020).

main mechanistic distinction from GTS-21 is that GTS-21 drives α7 into a desensitized state. Tropisetron behaves more as a positive allosteric modulator, sensitizing the receptor to endogenous ACh rather than fully occupying the orthosteric site (Callahan et al., 2017). That’s why adding cholinergic tone (nicotine, ALCAR) enhances rather than competes with its effects: you’re providing more substrate for a receptor that’s now better at responding to it.

The 5-HT3 axis is doing real work independently. 5-HT3 antagonism is pro-cognitive across multiple models (Arnsten et al., 1997; Barnes et al., 1990; Sridhar et al., 2002), likely via disinhibition of ACh release in prefrontal and hippocampal circuits. It’s also anxiolytic (Lecrubier et al., 1993; Olivier et al., 2000), antidepressant (Rajkumar & Mahesh, 2010), and the class as a whole (vortioxetine, ondansetron) shows durable cognitive and affective benefits without tolerance (Fakhfouri et al., 2019). There’s also a clinical signal for OCD: tropisetron augments fluvoxamine in treatment-refractory patients (Shalbafan et al., 2019), which fits mechanistically given 5-HT3’s role in compulsive circuitry.

not only that, but tropisetron activates SIRT1 (Mirshafa et al., 2020), NAD-dependent deacetylase responsible for the mediation of a lot of the downstream neuroprotective and anti-inflammatory machinery. adds a longevity angle that’s independent of the receptor pharmacology. And 5-HT3 blockade in the liver context improves obesity-associated fatty liver disease (Haub et al., 2011), so there’s metabolic benefit that’s easy to overlook when thinking about this purely as a nootropic. Dopaminergic at doses below 10mg, antidopaminergic above that (Lee et al., 1993).

The constipation is the main limiting factor. 5-HT3 blockade in the gut tanks motility (Lee et al., 1993), and it’s dose-dependent and cumulative. Intranasal administration dramatically cuts GI exposure while preserving CNS effects, since you’re bypassing first-pass gut exposure entirely. Oral is current; IN is the preferred route when available. Slow-release magnesium malate manages motility better than high-dose choline. Half-life is around 6 hours but functional effects outlast that. Effective range is 5-10mg.

• my personal anecdote has seen little of the constipation, could be due to the extreme amounts of Espresso i drink

Stacks: Nicotine (α7 synergy, extends and enhances (Callahan et al., 2017)), ALCAR (cholinergic tone, enhances memory effects), caffeine/PDE inhibitors (cAMP potentiates antidepressant effects), Usmarapride (5-HT3 antagonist + 5-HT4 agonist pairing for GI management)

Arnsten, A. F., Lin, C. H., Van Dyck, C. H., & Stanhope, K. J. (1997). The Effects of 5-HT3 Receptor Antagonists on Cognitive Performance in Aged Monkeys. Neurobiology of Aging, 18(1), 21–28. https://doi.org/10.1016/s0197-4580(96)00162-5

Barnes, J. M., Costall, B., Coughlan, J., Domeney, A. M., Gerrard, P. A., Kelly, M. E., Naylor, R. J., Onaivi, E. S., Tomkins, D. M., & Tyers, M. B. (1990). The Effects of Ondansetron, a 5-HT3 Receptor Antagonist, on Cognition in Rodents and Primates. Pharmacology, Biochemistry, and Behavior, 35(4), 955–962. https://doi.org/10.1016/0091-3057(90)90385-u

Callahan, P. M., Bertrand, D., Bertrand, S., Plagenhoef, M. R., & Terry, A. V. (2017). Tropisetron Sensitizes α7 Containing Nicotinic Receptors to Low Levels of Acetylcholine in Vitro and Improves Memory-Related Task Performance in Young and Aged Animals. Neuropharmacology, 117, 422–433. https://doi.org/10.1016/j.neuropharm.2017.02.025

Fakhfouri, G., Rahimian, R., Dyhrfjeld-Johnsen, J., Zirak, M. R., & Beaulieu, J.-M. (2019). 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. Pharmacological Reviews, 71(3), 383–412. https://doi.org/10.1124/pr.118.015487

Haub, S., Ritze, Y., Ladel, I., Saum, K., Hubert, A., Spruss, A., Trautwein, C., & Bischoff, S. C. (2011). Serotonin Receptor Type 3 Antagonists Improve Obesity-Associated Fatty Liver Disease in Mice. The Journal of Pharmacology and Experimental Therapeutics, 339(3), 790–798. https://doi.org/10.1124/jpet.111.181834

Kitagawa, H., Takenouchi, T., Azuma, R., Wesnes, K. A., Kramer, W. G., Clody, D. E., & Burnett, A. L. (2003). Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers. Neuropsychopharmacology, 28(3), 542–551. https://doi.org/10.1038/sj.npp.1300028

Lecrubier, Y., Puech, A. J., Azcona, A., Bailey, P. E., & Lataste, X. (1993). A Randomized Double-Blind Placebo-Controlled Study of Tropisetron in the Treatment of Outpatients with Generalized Anxiety Disorder. Psychopharmacology, 112(1), 129–133. https://doi.org/10.1007/BF02247373

Lee, C. R., Plosker, G. L., & McTavish, D. (1993). Tropisetron. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential as an Antiemetic. Drugs, 46(5), 925–943. https://doi.org/10.2165/00003495-199346050-00009

Mirshafa, A., Mohammadi, H., Shokrzadeh, M., Mohammadi, E., Talebpour Amiri, F., & Shaki, F. (2020). Tropisetron Protects against Brain Aging via Attenuating Oxidative Stress, Apoptosis and Inflammation: The Role of SIRT1 Signaling. Life Sciences, 248, 117452. https://doi.org/10.1016/j.lfs.2020.117452

Olivier, B., van Wijngaarden, I., & Soudijn, W. (2000). 5-HT(3) Receptor Antagonists and Anxiety; a Preclinical and Clinical Review. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology, 10(2), 77–95. https://doi.org/10.1016/s0924-977x(99)00065-6

Rajkumar, R., & Mahesh, R. (2010). The Auspicious Role of the 5-HT3 Receptor in Depression: A Probable Neuronal Target? Journal of Psychopharmacology, 24(4), 455–469. https://doi.org/10.1177/0269881109348161

Shalbafan, M., Malekpour, F., Tadayon Najafabadi, B., Ghamari, K., Dastgheib, S.-A., Mowla, A., Shirazi, E., Eftekhar Ardebili, M., Ghazizadeh-Hashemi, M., & Akhondzadeh, S. (2019). Fluvoxamine Combination Therapy with Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial. Journal of Psychopharmacology, 33(11), 1407–1414. https://doi.org/10.1177/0269881119878177

Sridhar, N., Veeranjaneyulu, A., Arulmozhi, D. K., Gupta, C. N. V. H. B., & Babu, R. J. (2002). 5-HT3 Receptors in Selective Animal Models of Cognition. Indian Journal of Experimental Biology, 40(2), 174–180.

van Haaren, F., Anderson, K. G., Haworth, S. C., & Kem, W. R. (1999). GTS-21, a Mixed Nicotinic Receptor Agonist/Antagonist, Does Not Affect the Nicotine Cue. Pharmacology, Biochemistry, and Behavior, 64(2), 439–444. https://doi.org/10.1016/s0091-3057(99)00054-4

Xia, L., Liu, L., Hong, X., Wang, D., Wei, G., Wang, J., Zhou, H., Xu, H., Tian, Y., Dai, Q., Wu, H. E., Chang, C., Wang, L., Kosten, T. R., & Zhang, X. Y. (2020). One-Day Tropisetron Treatment Improves Cognitive Deficits and P50 Inhibition Deficits in Schizophrenia. Neuropsychopharmacology, 45(8), 1362–1368. https://doi.org/10.1038/s41386-020-0685-0